A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Adebrelimab (Primary) ; SHR 1501 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 26 Sep 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Mar 2023.
- 19 Dec 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Mar 2023.